Rick Klaus­ner's crew of T cell spe­cial­ists wraps $425M IPO, hit­ting Nas­daq along­side Verve, Mol­e­c­u­lar Part­ners

It’s har­vest day for a pair of biotech star­tups with lofty goals to break new ground in can­cer and coro­nary heart dis­ease — and their high-pro­file founders.

Rick Klaus­ner’s Lyell Im­munophar­ma and Sek Kathire­san’s Verve Ther­a­peu­tics have both priced their IPOs, rais­ing $425 mil­lion and $266.7 mil­lion, re­spec­tive­ly. Nei­ther are in the clin­ic yet, but if their new­ly gained val­u­a­tions are any in­di­ca­tion, there is plen­ty of ap­petite for the kind of an­i­mal da­ta and bold ap­proach­es they of­fer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER